Hematologic Malignancies

Oncology·MeSH: Hematologic Neoplasms

18 drugs in development·12 companies·14 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Sirolimus	Filana Therapeutics Inc. (FLNA)
tafasitamab	Incyte Corp. (INCY)
Temsirolimus	Filana Therapeutics Inc. (FLNA)

Phase 2(4)

Drug	Company
Cytoxan	Filana Therapeutics Inc. (FLNA)
Mycophenolate mofetil	Filana Therapeutics Inc. (FLNA)
TIL	Filana Therapeutics Inc. (FLNA)
trichostatin a	Vanda Pharmaceuticals Inc. (VNDA)

Phase 1(6)

Drug	Company
calcineurin inhibitor	Incyte Corp. (INCY)
DVX201 (Unmodified Natural Killer Cells)	Coeptis Therapeutics Holdings Inc. (COEP)
hec89736	SUNSHINE BIOPHARMA INC. (SBFM)
tsc-102-a01	TScan Therapeutics, Inc. (TCRX)
tsc-102-a03	TScan Therapeutics, Inc. (TCRX)
tti-621	Trillium Therapeutics Inc. (TRIL)

Preclinical(2)

Drug	Company
cpi-482	CONSTELLATION PHARMACEUTICALS INC (CNST)
vadc45	Vor Biopharma Inc. (VOR)

Unknown(1)

Drug	Company
a multicenter access	HWH International Inc. (HWH)

Phase 1/Phase 2(2)

Drug	Company
Nemtabrutinib	Merck & Co., Inc. (MRK)
sls009	SELLAS Life Sciences Group, Inc. (SLS)

BioSniper tracks 18 drugs in development for Hematologic Malignancies across 12 companies.

There are 14 clinical trials targeting Hematologic Malignancies tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.